These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 17403537

  • 1. Bone marrow necrosis related to imatinib mesylate therapy for cml bilineal blast crisis.
    Campiotti L, Codari R, Appio L, Ultori C, Solbiati F, Maria Grandi A, Venco A.
    Leuk Res; 2007 Dec; 31(12):1768-70. PubMed ID: 17403537
    [No Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
    Higashi T, Tsukada J, Kato C, Iwashige A, Mizobe T, Machida S, Morimoto H, Ogawa R, Toda Y, Tanaka Y.
    Am J Hematol; 2004 Jul; 76(3):275-8. PubMed ID: 15224366
    [Abstract] [Full Text] [Related]

  • 3. Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
    Srinivas U, Pillai LS, Kumar R, Pati HP, Saxena R.
    Am J Hematol; 2007 Apr; 82(4):314-6. PubMed ID: 17013815
    [Abstract] [Full Text] [Related]

  • 4. Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
    Simpson E, O'Brien SG, Reilly JT.
    Clin Lab Haematol; 2006 Jun; 28(3):215-6. PubMed ID: 16706941
    [No Abstract] [Full Text] [Related]

  • 5. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S.
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adverse events after imatinib mesylate therapy.
    Burton C, Azzi A, Kerridge I.
    N Engl J Med; 2002 Feb 28; 346(9):712-3. PubMed ID: 11873781
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
    Ram R, Gafter-Gvili A, Okon E, Pazgal I, Shpilberg O, Raanani P.
    Acta Haematol; 2008 Feb 28; 119(2):104-7. PubMed ID: 18367829
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K, Takeuchi M, Koseki M, Uryu H.
    Ann Hematol; 2006 Aug 28; 85(8):542-4. PubMed ID: 16570152
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis.
    Rosado MF, Donna E, Ahn YS.
    J Clin Oncol; 2003 Aug 15; 21(16):3171-3. PubMed ID: 12915610
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
    Liu NS, O'Brien S.
    Leuk Lymphoma; 2002 Dec 15; 43(12):2413-5. PubMed ID: 12613534
    [Abstract] [Full Text] [Related]

  • 20. Imatinib mesylate as a cause of acute liver failure.
    Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D.
    Am J Hematol; 2006 Mar 15; 81(3):189-92. PubMed ID: 16493605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.